Closed-Loop Insulin Dosing With Dynamic ISF Adaptation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing insulin sensitivity factor-based systems lack accuracy and reliability, leading to increased risks of hyperglycemia and hypoglycemia due to inadequate insulin dose adjustments.

Innovation Solution

A control device that utilizes an Insulin Sensitivity Factor (ISF) as a function of measured blood glucose levels to determine personalized insulin recommendations, incorporating a retrieving unit, recommendation unit, and an insulin delivery unit, with features like autolearning and physiological models to adapt to individual user needs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If a fixed Insulin Sensitivity Factor is used, then the system is simple to operate, but the accuracy of insulin dosing deteriorates due to inability to adapt to individual physiological changes

Engineering Contradiction:

Improvesimplicity of system operationVSAvoidaccuracy of insulin dosing

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent transforms the fixed ISF into a dynamic parameter that automatically adjusts based on real-time blood glucose measurements and physiological state. The system continuously updates the ISF value through closed-loop control, allowing it to adapt to changing individual physiology while maintaining ease of use through automated adjustment rather than manual reconfiguration.

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The patent implements feedback mechanisms where blood glucose measurements are continuously monitored and fed back into the system to recalculate and update the ISF. This closed-loop feedback ensures the dosing accuracy adapts to individual physiological changes while the system remains operationally simple as the adjustment occurs automatically without user intervention.

Inventive Principle:

Principle #23Feedback

2Reliability

If personalized physiological models are implemented, then the reliability of glucose control improves, but the device complexity increases

Engineering Contradiction:

Improvereliability of glucose controlVSAvoidcomplexity of control system

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent implements self-service through automated physiological modeling where the system independently learns and adapts to each user's metabolic characteristics without requiring manual input or complex configuration. The automated algorithms continuously refine the personalized model using routine blood glucose data, achieving high reliability while keeping the user interface simple and the operational complexity manageable.

Inventive Principle:

Principle #25Self-service

3Manufacturing precision

If real-time physiological adjustments are made, then the precision of blood glucose management improves, but the computational requirements and system complexity increase

Engineering Contradiction:

Improveprecision of blood glucose managementVSAvoidcomputational complexity of system

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent focuses computational resources on dynamically adjusting key physiological parameters (ISF, baseline glucose, insulin sensitivity) rather than performing complex simulations. By changing these critical parameters in real-time based on blood glucose trends and physiological state, the system achieves precise glucose management with computationally efficient algorithms that maintain manageable system complexity.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentEP4651145A1Closed-loop blood glucose control systems and methods

Publication Date: 2025.11.19 DIABELOOP

Figure 1~2

AI summary

A control device (30) for determining a recommendation value of a control parameter of an insulin infusion device (20).